Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide - Merck & Co

Drug Profile

Temozolomide - Merck & Co

Alternative Names: CCRG-81045; MB-39831; MK-7365; NSC-362856; RP-46161; SCH-52365; Temcad; Temodal; Temodar; Temomedac

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MediciNova; Merck & Co; Schering-Plough; Stanford University; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Anaplastic astrocytoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Glioma; Malignant melanoma
  • Registered Ewing's sarcoma
  • Phase II Acute myeloid leukaemia
  • Phase I/II Glioblastoma
  • Phase I Gliosarcoma
  • No development reported Brain metastases; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer
  • Discontinued Non-Hodgkin's lymphoma; Prostate cancer; Sarcoma

Most Recent Events

  • 28 Feb 2019 Preregistration for Ewing's Sarcoma (Refractory metastatic disease, Recurrent) in Japan (PO, IV)
  • 21 Feb 2019 Registered for Ewing's Sarcoma (Recurrent, Refractory metastatic disease) in Japan (PO, IV)
  • 31 Dec 2018 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO) (NCT03782415)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top